Search

Your search keyword '"Frederic Thibault"' showing total 19 results
Start Over Author "Frederic Thibault"
19 results on '"Frederic Thibault"'

1. PD34-06 ROBOT-ASSISTED ARTIFICIAL URINARY SPHINCTER IMPLANTATION IN FEMALE PATIENTS: AN INTERNATIONAL MULTICENTER SERIES OF 182 PATIENTS

Author

Benoit Peyronnet, Jean-Nicolas Cornu, Olivier Belas, Grégoire Capon, Xavier Biardeau, Pierre Lecoanet, Luis Castro-Sader, Shahed Borojeni, Rainer Hein, Juliette Hascoet, null Frederic Thibault, Frederic Dubois, Vincent Cardot, Adrien Vidart, Aurélien Descazeaud, null Georges Fournier, and Frank Van der Aa

Subjects
Urology
Published
2022
Full Text
View/download PDF

2. Robot-assisted artificial urinary sphincter implantation in female patients: An international multicenter study

Author

Frederic Dubois, G. Robert, B. Peyronnet, V. Cardot, Marta Allué, Wouter Everaerts, Frederic Thibault, Xavier Biardeau, Georges Fournier, A. Vidart, Grégoire Capon, R. Hein, Olivier Belas, Pierre Lecoanet, A. Descazeaud, Andrea Manunta, Juliette Hascoet, Luis Castro-Sader, M. Daher, and F. Van Der Aa

Subjects
Artificial urinary sphincter, medicine.medical_specialty, Multicenter study, business.industry, Urology, Female patient, Medicine, business, lcsh:Diseases of the genitourinary system. Urology, lcsh:RC870-923, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282, Surgery
Published
2020

3. PD27-07 ROBOT-ASSISTED ARTIFICIAL URINARY SPHINCTER IMPLANTATION IN FEMALE PATIENTS: AN INTERNATIONAL MULTICENTER STUDY

Author

Benoit Peyronnet, Frank Van der Aa, Vincent Cardot, Grégoire Capon, Xavier Biardeau, Olivier Belas, Frederic Dubois, Juliette Hascoet, Vidart Adrien, Aurelien Descazeaud, Andrea Manunta, Luis Castro-Sader, Marta Allue, Frederic Thibault, Rainer Hein, Pierre Lecoanet, and Georges Fournier

Subjects
Artificial urinary sphincter, medicine.medical_specialty, Multicenter study, business.industry, Urology, Female patient, medicine, business, Surgery
Abstract

INTRODUCTION AND OBJECTIVE:The morbidity related to artificial urinary sphincter (AUS) implantation in women is usually considered as the drawback which has limited its widespread. In order to decr...

Published
2020
Full Text
View/download PDF

4. PD27-06 COMPARISON OF OPEN AND ROBOT-ASSISTED ARTIFICIAL URINARY SPHINCTER IMPLANTATION IN FEMALE PATIENTS WITH STRESS URINARY INCONTINENCE: A MULTICENTER STUDY

Author

L. Corbel, Emmanuel Della Negra, Jean-Nicolas Cornu, Georges Fournier, Olivier Belas, Juliette Hascoet, Philippe Grise, L. Peyrat, Frederic Thibault, V. Cardot, Aurélien Descazeaud, Thibaut Tricart, François Haab, Vidart Adrien, Anna Goujon, Grégoire Capon, Lucas Freton, Frederic Dubois, and Benoit Peyronnet

Subjects
Artificial urinary sphincter, medicine.medical_specialty, Multicenter study, business.industry, Urology, Urinary system, Female patient, medicine, Urinary incontinence, medicine.symptom, business
Abstract

INTRODUCTION AND OBJECTIVE:Several preliminary series have reported the use of a robotic approach for artificial urinary sphincter (AUS) implantation in female patients with stress urinary incontin...

Published
2020
Full Text
View/download PDF

5. High Visible Light Photoactivity of Plasma-Created Vanadium Clusters Supported on Nano-Zeolites

Author

Mohamad El-Roz, bazin philippe, Frederic Thibault-Starzyk, PERRIER, Nathalie, Laboratoire catalyse et spectrochimie (LCS), Centre National de la Recherche Scientifique (CNRS)-École Nationale Supérieure d'Ingénieurs de Caen (ENSICAEN), Normandie Université (NU)-Normandie Université (NU)-Institut de Chimie du CNRS (INC)-Université de Caen Normandie (UNICAEN), and Normandie Université (NU)

Subjects
[CHIM] Chemical Sciences, [CHIM]Chemical Sciences, ComputingMilieux_MISCELLANEOUS
Abstract

National audience

Published
2017

6. Effect of two injections of non-adjuvanted influenza A H1N1pdm2009 vaccine in renal transplant recipients: INSERM C09-32 TRANSFLUVAC trial

Author

Benoit Barrou, Frederic Thibault, Nicole Le Corre, Isabelle Charreau, Claire Pouteil Noble, Vincent Meiffrédy, Cécile Dollinger, David Bottigioli, Emmanuel Morelon, Jean-Pierre Aboulker, R. Cahen, Sameh Daoud, and Brigitte Autran

Subjects
Adult, Male, medicine.medical_specialty, Influenza vaccine, T-Lymphocytes, medicine.medical_treatment, Antibodies, Viral, medicine.disease_cause, Injections, Intramuscular, Gastroenterology, Young Adult, Influenza A Virus, H1N1 Subtype, Internal medicine, Influenza, Human, Influenza A virus, Humans, Medicine, Prospective Studies, Seroconversion, Kidney transplantation, Transplantation, General Veterinary, General Immunology and Microbiology, business.industry, Immunogenicity, Vaccination, Public Health, Environmental and Occupational Health, Immunosuppression, Hemagglutination Inhibition Tests, Middle Aged, medicine.disease, Kidney Transplantation, Infectious Diseases, Influenza Vaccines, Immunology, Molecular Medicine, Female, business
Abstract

Background Enhancing vaccine immunogenicity in kidney transplant recipients, particularly against influenza, is required since the immunosuppression used to prevent graft rejection limits vaccine immunogenicity. We therefore investigated the immunogenicity and safety of a double dose non-adjuvanted vaccination regimen against influenza H1N1pdm2009 in kidney transplant adult recipients. Methods A prospective single-arm study was conducted including 121 renal transplant recipients under triple immunosuppressive regimen. Patients received 2 injections (day 0, day 21) of an inactivated, non-adjuvanted H1N1pdm2009 vaccine. Immunogenicity (hemagglutination-inhibition [HI] antibodies and anti-hemagglutin [HA] specific T cells) was evaluated after one and two injections (day 21, day 42) and at 6 months (day 182). Results The seroprotection rate (HI antibody titer ≥ 1/40) was 19% at day 0 (n = 119), 53% at day 21 (n = 118), 60% at day 42 (n = 116) (p = 0.013; day 42 vs. day 21) and 56% at day 182 (n = 113). The seroconversion rate was 24% and 32%, the geometric mean fold rise was 3.7 and 4.6 after the first and second injections, respectively. T-cell immunity to the H1N1pdm2009 vaccine showed a two-fold increase from baseline, though not statistically significant, in H1N1pdm2009-HA-specific CD4+ and CD8+ T cells in 34% and 48% of cases, respectively. No rejection episodes related to vaccination were observed while the donor-specific antibodies and creatinine clearance remained unchanged throughout the study. Conclusion Administration of two doses of the non-adjuvanted influenza H1N1pdm2009 vaccine in renal transplant patients is safe and induces a significant seroprotection, not strong enough yet to meet European or US requirements for adults below 60 years, but comparable to seroprotection levels usually observed in the non immunosuppressed elderly population or conferred by a single dose of adjuvanted vaccine in solid organ transplant recipients. These results provide useful indications for future strategies required to improve immunogenicity of vaccines against influenza in transplanted patients.

Published
2012
Full Text
View/download PDF

7. New challenges in kidney cancer therapy: sunitinib

Author

Hassane Izzedine, Frederic Thibault, Olivier Rixe, and B. Billemont

Subjects
Oncology, medicine.medical_specialty, Pathology, Indoles, Antineoplastic Agents, Text mining, Internal medicine, Sunitinib, medicine, Humans, Pyrroles, Carcinoma, Renal Cell, Clinical Trials as Topic, business.industry, Hematology, Protein-Tyrosine Kinases, medicine.disease, Kidney Neoplasms, Receptors, Vascular Endothelial Growth Factor, Treatment Outcome, business, Kidney cancer, Forecasting, Kidney disease, medicine.drug
Published
2007
Full Text
View/download PDF

8. Infrared Study of the Silica/Silane Reaction

Author

Ei-Roz, M., Frederic Thibault-Starzyk, Blume, A., Elastomer Technology and Engineering, Faculty of Engineering Technology, Roland, Pascal, Laboratoire catalyse et spectrochimie (LCS), Centre National de la Recherche Scientifique (CNRS)-École Nationale Supérieure d'Ingénieurs de Caen (ENSICAEN), Normandie Université (NU)-Normandie Université (NU)-Institut de Chimie du CNRS (INC)-Université de Caen Normandie (UNICAEN), and Normandie Université (NU)

Subjects
in situ-FT-IR-Analysis, molecular modeling, IR-94401, [CHIM] Chemical Sciences, Silica/silane coupling reaction, [CHIM]Chemical Sciences, METIS-309336, METIS-301737, IR-88924
Abstract

International audience; The silica-silane system is used in modern tire tread compounds to improve wet grip and rolling resistance. An efficient silica / silane coupling during the mixing process is necessary to achieve the required in-rubber-properties. In order to understand this coupling reaction in detail, the silanol group density of the silica was characterized in depth. Furthermore, the reaction of a mercapto silane (Si 263 (R)) with two different silicas was studied with special infrared (IR) techniques. The infrared spectrum of the v (SiOH) region shows the behavior of SiOH groups during the reaction and contributes to clarify their role in the silane grafting reaction.

Published
2014

9. Advances in design and modelling of porous materials

Author

André Ayral, Sylvie Etienne-Calas, Benoit Coasne, Andre Deratani, Alexei Evstratov, Anne Galarneau, Daniel Grande, Matthieu Hureau, Hervé Jobic, Catherine Morlay, Julien Parmentier, Benedicte Prelot, Sylvie Rossignol, Simon-Masseron Angélique, Frederic Thibault-Starzyk, Institut Européen des membranes (IEM), Université Montpellier 2 - Sciences et Techniques (UM2)-Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Laboratoire Charles Coulomb (L2C), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Institut Charles Gerhardt Montpellier - Institut de Chimie Moléculaire et des Matériaux de Montpellier (ICGM ICMMM), Université Montpellier 1 (UM1)-Université Montpellier 2 - Sciences et Techniques (UM2)-Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Université Paris-Sorbonne (UP4), Institut de Chimie et des Matériaux Paris-Est (ICMPE), Institut de Chimie du CNRS (INC)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Centre National de la Recherche Scientifique (CNRS), Laboratoire Avancé de Spectroscopie pour les Intéractions la Réactivité et l'Environnement - UMR 8516 (LASIRE), Institut de Chimie du CNRS (INC)-Université de Lille-Centre National de la Recherche Scientifique (CNRS), Institut de recherches sur la catalyse et l'environnement de Lyon (IRCELYON), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Matériaux, ingénierie et science [Villeurbanne] (MATEIS), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS), Institut de Science des Matériaux de Mulhouse (IS2M), Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS), Axe 3 : organisation structurale multiéchelle des matériaux (SPCTS-AXE3), Science des Procédés Céramiques et de Traitements de Surface (SPCTS), Université de Limoges (UNILIM)-Ecole Nationale Supérieure de Céramique Industrielle (ENSCI)-Institut des Procédés Appliqués aux Matériaux (IPAM), Université de Limoges (UNILIM)-Université de Limoges (UNILIM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université de Limoges (UNILIM)-Ecole Nationale Supérieure de Céramique Industrielle (ENSCI)-Institut des Procédés Appliqués aux Matériaux (IPAM), Université de Limoges (UNILIM)-Université de Limoges (UNILIM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Matériaux à Porosité Contrôlée (LMPC), Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Ecole Nationale Supérieure de Chimie de Mulhouse-Centre National de la Recherche Scientifique (CNRS), Laboratoire catalyse et spectrochimie (LCS), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-École Nationale Supérieure d'Ingénieurs de Caen (ENSICAEN), Normandie Université (NU)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Calas-Etienne, Sylvie, Centre National de la Recherche Scientifique (CNRS)-Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Institut de Chimie du CNRS (INC)-Université de Montpellier (UM), Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)-Université Montpellier 1 (UM1)-Université Montpellier 2 - Sciences et Techniques (UM2)-Institut de Chimie du CNRS (INC), Institut de Chimie du CNRS (INC)-Université de Lille-Centre National de la Recherche Scientifique (CNRS)-Centrale Lille Institut (CLIL), Institut des Procédés Appliqués aux Matériaux (IPAM), Université de Limoges (UNILIM)-Université de Limoges (UNILIM)-Ecole Nationale Supérieure de Céramique Industrielle (ENSCI)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université de Limoges (UNILIM)-Institut des Procédés Appliqués aux Matériaux (IPAM), Université de Limoges (UNILIM)-Université de Limoges (UNILIM)-Ecole Nationale Supérieure de Céramique Industrielle (ENSCI)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université de Limoges (UNILIM), Centre National de la Recherche Scientifique (CNRS)-École Nationale Supérieure d'Ingénieurs de Caen (ENSICAEN), Normandie Université (NU)-Normandie Université (NU)-Institut de Chimie du CNRS (INC)-Université de Caen Normandie (UNICAEN), Normandie Université (NU), Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Matériaux et Nanosciences Grand-Est (MNGE), Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Réseau nanophotonique et optique, and Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)

Subjects
[PHYS.COND.CM-MS]Physics [physics]/Condensed Matter [cond-mat]/Materials Science [cond-mat.mtrl-sci], [PHYS.COND.CM-MS] Physics [physics]/Condensed Matter [cond-mat]/Materials Science [cond-mat.mtrl-sci], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2014

10. Régression d’un thrombus cave néoplasique sous traitement par sorafénib

Author

Hassane Izzedine, Marc-Olivier Bitker, V. Sultan, O. Rixe, Frederic Thibault, B. Billemont, and S. Bart

Subjects
Nephrology, medicine.medical_specialty, business.industry, Urology, medicine.medical_treatment, medicine.disease, Nephrectomy, Surgery, Venous thrombosis, Internal medicine, cardiovascular system, medicine, cardiovascular diseases, Thrombus, Venae cavae, business, Kidney cancer, Dialysis, Kidney disease
Abstract

Ten percent of patients with kidney cancer have associated vena cava thrombus, which is associated with a high operative morbidity. Up to now, no medical treatment has allowed regression of vena cava tumour thrombus. The authors report the case of a 62-year-old patient with left kidney cancer associated with vena cava tumour thrombus. After surgical resection, the patient relapsed in the form of vena cava thrombus associated with right renal vein thrombus, responsible for renal insufficiency requiring dialysis. Sorafenib therapy allowed regression of the vena cava thrombus, suspension of haemodialysis and local disease control with a follow-up of one year. This case report justifies a review of the place of anti-angiogenic therapy in the treatment of kidney cancer.

Published
2008
Full Text
View/download PDF

12. Regression of brain metastases of renal cell carcinoma with antiangiogenic therapy

Author

Frederic Thibault, B. Billemont, and O. Rixe

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Angiogenesis, business.industry, Sunitinib, medicine.medical_treatment, Urology, Phases of clinical research, medicine.disease, Nephrectomy, Metastasis, Lesion, Neurology, Renal cell carcinoma, Internal medicine, medicine, Carcinoma, Neurology (clinical), medicine.symptom, business, medicine.drug
Abstract

We report the occurrence of a major volume reduction of cerebelar metastasis after 6 weeks of treatment with the antiangiogenic compound sunitinib [1], an oral inhibitor of several tyrosine kinases, including vascular endothelial growth factor receptor (VEGFR) and platelet derived growth factor receptor (PDGFR). A 60-year-old female presented in June 2003 with a tumor developed in the left kidney. There were no distant metastases on total body CT-scan. A radical nephrectomy was performed. The pathological exam found a 9 cm clearcell carcinoma (Furhman grade 4). In May 2005, the patient presented difficulties walking. Brain MRI was performed and two focal lesions were found: the right cerebelar lesion was removed and the right frontal lesion was treated by stereotaxic radiation therapy. Bone metastases (right femoral head) were treated by IV bisphosphonates. In October 2006, 40 months later after the initial diagnosis, two new cerebellar lesions were found on a brain MRI. The right frontal lesion had remained stable (Fig. 1a) .We began a treatment with SUNITINIB 50 mg a day given orally over a period of four weeks. MRI evaluation at week 6 showed a significant regression of the two cerebelar lesions associated with necrosis (Fig. 1b). The frontal lesion remained stable. The treatment with SUNITINIB was then continued alternating with 2-weeks rest periods. Sunitib has demonstrated a significant advantage over interferon-a for the treatment of metastatic RCC in a large phase 3 study [2]. There is a lack of information about sunitinib efficacy on brain metastases because patients with brain metastases were systematically excluded from previous studies. Brain metastases are refractory to most conventional chemotherapy regimens given for the treatment of solid tumors [3]. Putative activity of anti-angiogenic therapy on brain metastases is controversial. VEGF and all the mechanisms pulling (entailing) a dysregulation of the local angiogenesis participate in a global increase of the permeability of the BBB [4]. This increase of BBB permeability allows pericytes from peripheral blood to participate in the forming of neo-vessels intended for the tumor irrigation. VEGF also plays a major role in the brain revascularisation after an ischemic accident by increasing the permeability of the BBB, through NO synthetase [5]. Our observations suggest that sunitinib has significant benefit for the treatment of brain metastases. The safety and the efficacy of this strategy should be addressed in a future prospective trial. We thank the Fondation Martine Midy for support of this study.

Published
2007
Full Text
View/download PDF

13. Isomorphous Substitution of Framework Atoms by Titanium in VPI-5 Aluminophosphate Molecular Sieve

Author

Nataša Novak Tušar, Nataša Zabukovec Logar, Iztok Arčon, Frederic Thibault-Starzyk, Venčeslav Kaučič, Nataša Novak Tušar, Nataša Zabukovec Logar, Iztok Arčon, Frederic Thibault-Starzyk, and Venčeslav Kaučič

Abstract

Extra-large pore aluminophosphate molecular sieve TiVPI-5 was synthesised hydrothermally in the presence of di-n-butylamine and transformed by the calcination process at 500 °C to a large pore TAPO-8. Incorporation of titanium(IV) into VPI-5 framework was studied by elemental and thermogravimetric analyses, combined with X-ray Absorption Near Edge Structure (XANES) spectroscopy and UV-VIS absorption spectroscopy. We found that titanium(IV) incorporated in TiVPI-5 isomorphously substitutes framework aluminium on octahedral sites and that it is not present in the structure in the form of TiO2 anatase. In situ IR measurements of pyridine adsorption/desorption were used to check the presence of catalytically active centres in the product resulting from titanium incorporation into the VPI-5 framework. Weak Lewis and Brønsted acid sites were found in small amounts in the calcined product TAPO-8.

Published
2001

18. Matériaux micro et mésoporeux : Caractérisation

Author

Frédéric Thibault-Starzyk and Frédéric Thibault-Starzyk

Subjects
Zeolites, Membranes (Technology)
Abstract

Cet ouvrage complet est consacré aux méthodes de caractérisation des matériaux microporeux : il permet une mise à niveau des connaissances sur la base des développements récents de ce secteur et propose également de découvrir la richesse de ce nouvel univers, de plus en plus présent dans l'industrie et la vie quotidienne.

Published
2004

19. Kinetic measurements and operando IR: what are the limits for measuring TOF and quantum yield in heterogeneous photocatalysis?

Author

Mohamad El-Roz, bazin philippe, Frederic Thibault-Starzyk, Laboratoire catalyse et spectrochimie (LCS), Centre National de la Recherche Scientifique (CNRS)-École Nationale Supérieure d'Ingénieurs de Caen (ENSICAEN), Normandie Université (NU)-Normandie Université (NU)-Institut de Chimie du CNRS (INC)-Université de Caen Normandie (UNICAEN), Normandie Université (NU), and PERRIER, Nathalie

Subjects
[CHIM] Chemical Sciences, [CHIM]Chemical Sciences, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Catalog

Books, media, physical & digital resources
See catalog results